A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis

Peptides

Volumn 54, Issue , 2014, Pages 19-26

  Tashiro, Yuko ^a   Sato, Kengo ^a   Watanabe, Takuya ^a   Nohtomi, Kyoko ^b   Terasaki, Michishige ^b   Nagashima, Masaharu ^b   Hirano, Tsutomu ^b  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Exendin 4; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Liraglutide; Macrophage

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE 1; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; GASTRIC INHIBITORY POLYPEPTIDE (1-42); GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HORMONE RECEPTOR; PEPTIDE; PEPTIDE FRAGMENT; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; AORTA WALL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FOAM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SMOOTH MUSCLE FIBER; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; ATHEROSCLEROSIS; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE; FEMALE; FOAM CELLS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MICE, MUTANT STRAINS; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; VENOMS;

EID: 84893424204     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.12.015     Document Type: Article

References (37)

1. M. Arakawa, T. Mita, K. Azuma, C. Ebato, H. Goto, and T. Nomiyama et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4 Diabetes 59 2010 1030 1037
2. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350 (Pubitemid 351653542)
3. S.Y. Chang, D.B. Kim, G.R. Ryu, S.H. Ko, I.K. Jeong, and Y.B. Ahn et al. Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway J Cell Biochem 114 2013 844 853
4. K.C. Dozier, E.L. Cureton, R.O. Kwan, B. Curran, J. Sadjadi, and G.P. Victorino Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation Peptides 30 2009 1735 1741
5. D.J. Drucker The biology of incretin hormones Cell Metab 3 2006 153 165
6. O. Erdogdu, D. Nathanson, A. Sjoholm, T. Nystrom, and Q. Zhang Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor Mol Cell Endocrinol 325 2010 26 35
7. -/- mouse model Diab Vasc Dis Res 8 2011 117 124
8. -/- mouse model Diab Vasc Dis Res 10 2013 353 360
9. H. Goto, T. Nomiyama, T. Mita, E. Yasunari, K. Azuma, and K. Komiya et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury Biochem Biophys Res Commun 405 2011 79 84
10. M.K. Gutniak, H. Larsson, S.J. Heiber, O.T. Juneskans, J.J. Holst, and B. Ahren Potential therapeutic levels of glucagon-like peptide 1 achieved in humans by a buccal tablet Diabetes Care 19 1996 843 848 (Pubitemid 26286990)
11. J.J. Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 2007 1409 1439 (Pubitemid 350041474)
12. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 60 2008 470 512
13. L.B. Knudsen Liraglutide: the therapeutic promise from animal models Int J Clin Pract Suppl 167 2010 4 11
14. H. Konii, K. Sato, S. Kikuchi, H. Okiyama, R. Watanabe, and A. Hasegawa et al. Stimulatory effects of cardiotrophin-1 on atherosclerosis Hypertension 62 2013 942 950
15. M. Laudes, F. Oberhauser, D.M. Schulte, K. Schilbach, S. Freude, and R. Bilkovski et al. Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects Exp Clin Endocrinol Diabetes 118 2010 473 477
16. S. Lee, D. Yabe, K. Nohtomi, R. Morita, Y. Seino, and T. Hirano Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes Endocr J 57 2010 119 126
17. S. Lim, S.H. Choi, H. Shin, B.J. Cho, H.S. Park, and B.Y. Ahn et al. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats PLoS ONE 7 2012 e35007
18. H. Liu, A.E. Dear, L.B. Knudsen, and R.W. Simpson A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules J Endocrinol 201 2009 59 66
19. M. Malm-Erjefält, I. Bjørnsdottir, J. Vanggaard, H. Helleberg, U. Larsen, and B. Oosterhuis et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase Drug Metab Dispos 38 2010 1944 1953
20. J. Matsubara, S. Sugiyama, K. Sugamura, T. Nakamura, Y. Fujiwara, and E. Akiyama et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice J Am Coll Cardiol 59 2012 265 276
21. M. Nagashima, T. Watanabe, M. Shichiri, K. Sato, Y. Shiraishi, and R. Morita et al. Chronic infusion of salusin-α and -β exerts opposite effects on macrophage foam cell formation and atherosclerosis in apolipoprotein E-deficient mice Atherosclerosis 212 2010 70 77
22. M. Nagashima, T. Watanabe, M. Terasaki, M. Tomoyasu, K. Nohtomi, and J. Kim-Kaneyama et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice Diabetologia 54 2011 2649 2659
23. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, and A.M. Riazi et al. GLP-1 agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
24. M.H. Noyan-Ashraf, E.A. Shikatani, I. Schuiki, I. Mukovozov, J. Wu, and R.K. Li et al. A glucagon-like peptide-1 analogue reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity Circulation 127 2013 74 85
25. T. Nystrom, M.K. Gutniak, Q. Zhang, E. Zhang, J.J. Holst, and B. Ahren et al. Effects of glucagon like peptide on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab 287 2004 E1209 E1215
26. F.E. Palmieri, and P.E. Ward Dipeptidyl(amino)peptidase IV and post proline cleaving enzyme in cultured endothelial and smooth muscle cells Adv Exp Med Biol 247A 1989 305 311
27. -/- mice Endocrinology 154 2013 127 139
28. D. Shiraishi, Y. Fujiwara, Y. Komohara, H. Mizuta, and M. Takeya Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation Biochem Biophys Res Commun 425 2012 304 308
29. A. Shiraki, J. Oyama, H. Komoda, M. Asaka, A. Komatsu, and M. Sakuma et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells Atherosclerosis 221 2012 375 382
30. G.G. Sokos, H. Bolukoglu, J. German, T. Hentosz, G.J. Magovern Jr., and T.D. Maher et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting Am J Cardiol 100 2007 824 829 (Pubitemid 47268274)
31. M. Terasaki, M. Nagashima, T. Watanabe, A. Miyazaki, and T. Hirano Preventive effects of dipeptidyl peptidase-4 inhibitor on the development of atherosclerotic lesions in apolipoprotein E-null mice Metabolism 61 2012 974 977
32. M. Terasaki, M. Nagashima, K. Nohtomi, K. Kohashi, M. Tomoyasu, and K. Sinmura et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice PLoS ONE 8 2013 e70933
33. R.L. Tiwari, V. Singh, and M.K. Barthwal Macrophages: an elusive yet emerging therapeutic target of atherosclerosis Med Res Rev 28 2008 483 544 (Pubitemid 351842141)
34. T. Watanabe, T. Suguro, T. Kanome, Y. Sakamoto, S. Kodate, and T. Hagiwara et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages Hypertension 46 2005 738 744 (Pubitemid 43186747)
35. T. Watanabe, K. Nishio, T. Kanome, T.A. Matsuyama, S. Koba, and T. Sakai et al. Impact of salusin-α and -β on human macrophage foam cell formation and coronary atherosclerosis Circulation 117 2008 638 648
36. 1 on macrophage foam cell formation and atherosclerosis Circ Res 105 2009 500 510
37. Y. Zhao, X. Chen, H. Yang, L. Zhou, E.U. Okoro, and Z. Guo A novel function of apolipoprotein E: upregulation of ATP-binding cassette transporter A1 expression PLoS ONE 6 2011 e21453